Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Imarc Group
www.imarcgroup.com/
Kanika Sharma
sales@imarcgroup.com
8130434268
GB Nagar
Nehru Complex

Bookmark and Share
Trypanosomiasis (sleeping sickness) Market Size, Drug Pipeline Developments and Trends 2025-3035
The trypanosomiasis (sleeping sickness) market reached a value of USD 64.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024.

BriefingWire.com, 7/04/2025 - The trypanosomiasis (sleeping sickness) market reached a value of USD 64.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 127.0 Million by ?2035?, exhibiting a growth rate (CAGR) of 6.39% during ?2025-2035?.

A breakthrough development in 2025 is the wider use of Fexinidazole Winthrop, the first all-oral therapy for Trypanosoma brucei (T.b.) rhodesiense sleeping sickness. It was Sanofi's and the for Neglected Diseases initiative’s (DNDi) collaborative project that earned a positive scientific opinion from the European Medicines Agency in December 2023 for Fexinidazole's use in T.b. rhodesiense. It was incorporated into WHO treatment guidelines as the first-choice therapy in June 2024. Fexinidazole's Zonal Marketing Authorization allowed importation and distribution in Ethiopia, Malawi, and Zimbabwe in early 2025, revolutionizing treatment by replacing toxic intravenous medications that required hospitalization with oral . This transition to full oral and single-dose therapy represents a paradigm shift in HAT management. Oral therapy simplifies the need for complex medical infrastructure and reduces the need for skilled personnel, addressing the scarcity of trained healthcare professionals in under-resourced regions.

Progress is being made on clinical trials for acoziborole and studies in children, with step 2 of the ACOZI-KIDS study commencing in late 2024 with recruitment goals set for early 2025. The public-private partnership model, which includes entities such as Sanofi, DNDi, WHO, and various national programs, serves for Fexinidazole and acoziborole demonstrates proactively tackling neglected diseases and is along the lines of what is needed to overcome the commercial disincentives bound to NTD drug development are proven useful turn serves as a precedent and supports global health innovation framework

Request for a sample of this report: https://www.imarcgroup.com/trypanosomiasis-sleeping-sickness-market/requestsample

Countries Covered:

United States

Germany

France

United Kingdom

Italy

Spain

Japan

This report also provides a detailed analysis of the current trypanosomiasis (sleeping sickness) marketed and late-stage pipeline .

In-Market :

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline :

Drug overview

Mechanism of action

Regulatory status

Clinical trial results

Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the trypanosomiasis (sleeping sickness) market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Sanofi

Ask the Analyst for Customization and Explore the Full Report with TOC: Trypanosomiasis (sleeping sickness) Drugs Analysis Market Epidemiology

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2025 Proserve Technology, Inc.